- LifeSci Capital analyst Charles Zhu has reiterated a buy rating on BlossomHill Therapeutics with a price target of 32.00 USD.
- The rating is supported by updated clinical data from the SOLARA phase 1 / 2 study of BH-30643 in C797S mutation patients, showing a median overall response rate of around 40 % and promising treatment durability.
- Additional factors include manageable safety profiles, a clear path toward accelerated approval discussions in late 2026, and a new buy rating from Guggenheim with a 30.00 USD target.
